Jacob A Doll1, Megan L Neely2, Matthew T Roe3, Paul W Armstrong4, Harvey D White5, Dorairaj Prabhakaran6, Kenneth J Winters7, Suman Duvvuru7, Scott S Sundseth8, Joseph A Jakubowski7, Paul A Gurbel9, Deepak L Bhatt10, E Magnus Ohman3, Keith A A Fox11. 1. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina. 4. Canadian VIGOUR Centre, Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 5. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand. 6. Centre for Chronic Disease Control and Public Health Foundation of India, New Delhi, India. 7. Eli Lilly and Company, Indianapolis, Indiana. 8. Cabernet Pharmaceuticals, Chapel Hill, North Carolina. 9. Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, Virginia. 10. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. 11. British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland, United Kingdom. Electronic address: k.a.a.fox@ed.ac.uk.
Abstract
BACKGROUND: Certain alleles of the CYP2C19 gene are associated with higher platelet reactivity and increased ischemic events among patients treated with clopidogrel. However, the relationship of CYP2C19 genotype and outcomes in medically managed patients with acute coronary syndromes (ACS) is not known. OBJECTIVES: This study sought to assess the effect of CYP2C19 genotype on ischemic outcomes in patients with ACS initially managed medically without revascularization who were randomized to either clopidogrel or prasugrel. METHODS: We classified patients as extensive metabolizers (EM) or reduced metabolizers (RM) based on CYP2C19 genotype and evaluated ischemic outcomes and platelet reactivity. Among 9,326 patients enrolled from 2008 to 2011, 5,736 participated in the genetics cohort; of these, 2,236 had platelet function testing data. RESULTS: There was no association between CYP2C19 metabolizer status (EM vs. RM) and the primary composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke (hazard ratio [HR]: 0.86). EM and RM patients had similar rates of the primary endpoint whether treated with prasugrel (HR: 0.82) or clopidogrel (HR: 0.91; p for interaction = 0.495). After adjusting for clinical and treatment variables, EM patients had a lower risk of MI versus RM patients (HR: 0.80), but risks of other outcomes were similar. RM patients had significantly higher mean P2Y12 reaction units versus EM patients when treated with clopidogrel (39.93), but not with prasugrel (3.87). CONCLUSIONS: CYP2C19 metabolizer status is not associated with the composite outcome of cardiovascular death, MI, or stroke in medically managed ACS patients treated with clopidogrel or prasugrel. Our findings do not support routine CYP2C19 genetic testing in this population. (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects [TRILOGY ACS]; NCT00699998).
RCT Entities:
BACKGROUND: Certain alleles of the CYP2C19 gene are associated with higher platelet reactivity and increased ischemic events among patients treated with clopidogrel. However, the relationship of CYP2C19 genotype and outcomes in medically managed patients with acute coronary syndromes (ACS) is not known. OBJECTIVES: This study sought to assess the effect of CYP2C19 genotype on ischemic outcomes in patients with ACS initially managed medically without revascularization who were randomized to either clopidogrel or prasugrel. METHODS: We classified patients as extensive metabolizers (EM) or reduced metabolizers (RM) based on CYP2C19 genotype and evaluated ischemic outcomes and platelet reactivity. Among 9,326 patients enrolled from 2008 to 2011, 5,736 participated in the genetics cohort; of these, 2,236 had platelet function testing data. RESULTS: There was no association between CYP2C19 metabolizer status (EM vs. RM) and the primary composite endpoint of cardiovascular death, myocardial infarction (MI), or stroke (hazard ratio [HR]: 0.86). EM and RM patients had similar rates of the primary endpoint whether treated with prasugrel (HR: 0.82) or clopidogrel (HR: 0.91; p for interaction = 0.495). After adjusting for clinical and treatment variables, EM patients had a lower risk of MI versus RMpatients (HR: 0.80), but risks of other outcomes were similar. RM patients had significantly higher mean P2Y12 reaction units versus EM patients when treated with clopidogrel (39.93), but not with prasugrel (3.87). CONCLUSIONS:CYP2C19 metabolizer status is not associated with the composite outcome of cardiovascular death, MI, or stroke in medically managed ACS patients treated with clopidogrel or prasugrel. Our findings do not support routine CYP2C19 genetic testing in this population. (A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects [TRILOGY ACS]; NCT00699998).
Authors: Thomas J Povsic; E Magnus Ohman; Matthew T Roe; Jennifer White; Frank W Rockhold; Gilles Montalescot; Jan H Cornel; Jose C Nicolau; P Gabriel Steg; Stefan James; Christoph Bode; Robert C Welsh; Alexei N Plotnikov; Hardi Mundl; C Michael Gibson Journal: JAMA Cardiol Date: 2019-07-01 Impact factor: 14.676
Authors: Scott J Cameron; Doran S Mix; Sara K Ture; Rachel A Schmidt; Amy Mohan; Daphne Pariser; Michael C Stoner; Punit Shah; Lijun Chen; Hui Zhang; David J Field; Kristina L Modjeski; Sandra Toth; Craig N Morrell Journal: Arterioscler Thromb Vasc Biol Date: 2018-05-03 Impact factor: 8.311
Authors: Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson Journal: JACC Cardiovasc Interv Date: 2017-11-01 Impact factor: 11.195
Authors: Nita A Limdi; Larisa H Cavallari; Craig R Lee; William B Hillegass; Ann M Holmes; Todd C Skaar; Maria Pisu; Chrisly Dillon; Amber L Beitelshees; Philip E Empey; Julio D Duarte; Vakaramoko Diaby; Yan Gong; Julie A Johnson; John Graves; Shawn Garbett; Zilu Zhou; Josh F Peterson Journal: Pharmacogenomics J Date: 2020-02-11 Impact factor: 3.550
Authors: Khoa A Nguyen; Michael T Eadon; Ryan Yoo; Evan Milway; Allison Kenneally; Kevin Fekete; Hyun Oh; Khanh Duong; Elizabeth C Whipple; Titus K Schleyer Journal: Clin Transl Sci Date: 2020-12-05 Impact factor: 4.689
Authors: Larisa H Cavallari; Francesco Franchi; Fabiana Rollini; Latonya Been; Andrea Rivas; Malhar Agarwal; D Max Smith; Kimberly Newsom; Yan Gong; Amanda R Elsey; Petr Starostik; Julie A Johnson; Dominick J Angiolillo Journal: J Transl Med Date: 2018-04-11 Impact factor: 5.531